31. Colmers IN, Bowker SL, Johnson JA, et al. Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2012;38(6):475-484.

32. Mamtani R, Haynes K, Bilker WB, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst. 2012;104(18):1411-1421.

Continue Reading

33. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29(2):254-258.

34. Yang Y-X, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004;127(4):1044-1050.

35. Chang C-H, Toh S, Lin JW, et al. Cancer risk associated with insulin glargine among adult type 2 diabetes patients—a nationwide cohort study. PLoS One. 2011;6(6):e21368.

36. Colmers IN, Bowker SL, Tjosvold LA, et al. Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab. 2012;38(6):485-506.

37. Yang X-L, Chan JC. Diabetes, insulin and cancer risk. World J Diabetes. 2012;3(4):60-64.

38. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27(7):1535-1540.

39. Onitilo AA, Engel JM, Glurich I, et al. Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control. 2012;23(7):991-1008.